|
Re: Genentech update on T-DMI early access program
I'm worried and concerned about the starting of the Theresa phase III trial, does this means that all stage IV breast cancer her2 must wait the end of this trial and its results in order to get access toT-DM1 or there is a hope for the drug being approved sooner than the daunting 3.5 years time frame for the trial to be closed?
I'm not sure what this means, but how did the things go from fast tracking, to 1-2 years waiting and now this whooping 3.5 years or more delay?
__________________
Son of Ha
She has been dignosed in February 2008 BC state IV, left breast multiple nodes size 5 cm, mets lungs and liver. Er+ Pr+ Her neu +++.
3/2008 - 10/2010 Herceptin + Aramidex NED
10/2010 recurrence lung met, pleural effusion, toracentesis
11/2010- Tyverb + Navalbine NED
08/2011 CA-15-3 = 90 scan
08/2011 Scan revealed reccurrence lung met, tiny metastasis on the pleura and pleural effusion.
4 pills tyverb, mytoxantrone once ever three weeks, and Aromasin.
Tykerb and taxol, sever allergic reaction
Tykerb taxotere
Herceptin, perjeta, gemcitabina
C- diff, bad diarrea
Halevan and tamoxifen, tm down from 1200 to 130
|